{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-000836","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.374681+00:00","generated_at":"2026-06-07T02:55:01.648864+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed reports prelim 2023 ARIKAYCE sales of ~$305.2M; guides 2024 to $340-360M","bullets":["ARIKAYCE 2023 global net sales ~$305.2M, exceeding upper end of guidance, 24% YoY growth.","2024 ARIKAYCE revenue guidance $340-360M (midpoint 15% growth).","Phase 3 ASPEN (brensocatib) topline data expected latter part of Q2 2024; potential U.S. launch mid-2025.","TPIP Phase 2 PH-ILD study enrollment completed (39 patients); topline data expected Q2 2024.","Phase 3 ENCORE (ARIKAYCE label expansion) topline readout expected 2025; FDA feedback received on ARISE."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-000836","json":"https://secwatch.observer/filing/0001140361-24-000836.json","markdown":"https://secwatch.observer/filing/0001140361-24-000836.md","text":"https://secwatch.observer/filing/0001140361-24-000836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124000836/0001140361-24-000836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124000836/ef20017898_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:55:01.648864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}